Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 50 versus CD4 ≥ 50 cellsmm3 英文参考文献.docVIP

下载本文档

7
0
约 8页
2017-05-13 发布于上海
举报
版权申诉

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 50 versus CD4 ≥ 50 cellsmm3 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 50 versus CD4 ≥ 50 cellsmm3 英文参考文献

AIDS Research and Therapy BioMedCentral Research Open Access Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 50 versus CD4 ≥ 50 cells/mm3 Weerawat Manosuthi*1, Sukanya Chimsuntorn1, Sirirat Likanonsakul1 and Somnuek Sungkanuparph2 Address: 1Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand and 2Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand Email: Weerawat Manosuthi* - drweerawat@; Sukanya Chimsuntorn - drskychim@; Sirirat Likanonsakul - dimvbi@moph2.moph.go.th; Somnuek Sungkanuparph - rasuy@mahidol.ac.th * Corresponding author Published: 13 March 2007 Received: 21 December 2006 Accepted: 13 March 2007 AIDS Research and Therapy 2007, 4:6 doi:10.118 6/1742-6405-4-6 This article is available from: /content/4/1/6 ? 2007 Manosuthi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of stavudine (d4T)/lamivudine (3TC)/nevirapine (NVP) is widely used in developing countries. The clinical data of this FDC among very advanced HIV-infected patients is limited. Methods: A retrospective cohort study was conducted among ART-na?ve HIV-infected patients who were initiated a generic FDC of d4T/3TC/NVP between May 2004 and October 2005. Patients were categorized into 2 groups according to the baseline CD4 (group A: 50 cell/mm3 and group B:≥ 50 cell/mm3). Results: There were 204 patients with a mean ± SD age of 37.1 ± 8 .9 years, 120 (58 .8 %) in group A and 8 4 (41.2%) in group B. Median (IQR) CD4 cell count